Kilbourne F153: A/NWS/34 (HA) x A/Rockefeller Institute/5/57 (NA) (H1N2), Reassortant X-7(F1)L, High NA, Large Plaque

Catalog No. NR-3591

Derived from NIAID Catalog No. V-331-0E5437

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases, National Institutes of Health

Product Description:

Virus Classification: *Orthomyxoviridae, Influenzavirus A*
Species: Influenza A virus
Reassortant: A/NWS/34 (HA) x A/Rockefeller Institute/5/57 (NA) (H1N2), high NA, large plaque (L) reassortant [Kilbourne F153; X-7(F1)L][1-3]
Comments:[1-3] X-7(F1) is a backcross (F1 generation) of reassortant X-7 with its H2N2 parent, A/Rockefeller Institute/5/57, resulting in a reassortant with an increased amount of neuraminidase (NA) per virion. X-7(F1) produces large plaques in Madin-Darby canine kidney (MDCK) cells.

Material Provided:

Each vial contains approximately 1 mL of pooled allantoic fluid from specific-pathogen free (SPF) embryonated chicken eggs infected with a high NA, large plaque (L) reassortant (Kilbourne F153) of influenza A virus, A/NWS/34 (HA) x A/Rockefeller Institute/5/57 (NA) (H1N2).

Packaging/Storage:

NR-3591 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -70°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Host: 9 to 11-day-old SPF embryonated chicken eggs
Infection: Embryonated chicken eggs must be candled for viability prior to inoculation
Incubation: 1 to 3 days at 35°C in a humidified chamber without CO_2
Effect: Hemagglutination activity using chicken red blood cells and allantoic fluid from infected embryonated chicken eggs

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Kilbourne F153: A/NWS/34 (HA) x A/Rockefeller Institute/5/57 (NA) (H1N2), Reassortant X-7(F1)L, High NA, Large Plaque, NR-3591."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. http://www.flu-archive.org/data_sheets/F153.doc
2. http://www.flu-archive.org/
3. http://www.flu-archive.org/search/results.pl?search_string=&join_type=and
4. Kilbourne, E. D., et al. "Antiviral Activity of Antiserum Specific for an Influenza Virus Neuraminidase." J. Virol.

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org
800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org

2 (1968): 281-288. PubMed: 4911843.
5. Schulman, J. L., M. Khakpour, and E. D. Kilbourne. "Protective Effects of Specific Immunity to Viral Neuraminidase on Influenza Virus Infection of Mice." J. Virol. 2 (1968): 778-786. PubMed: 5701819.
6. Schulman, J. L. and E. D. Kilbourne. "Independent Variation in Nature of Hemagglutinin and Neuraminidase Antigens of Influenza Virus: Distinctiveness of Hemagglutinin Antigen of Hong Kong/68 Virus." Proc. Natl. Acad. Sci. U.S.A. 63 (1969): 326-333. PubMed: 5257124.
7. Kilbourne, E. D., et al. "Influenza Virus Polypeptides and Antigens - Summary of Influenza Workshop I." J. Infect. Dis. 125 (1972): 447-455.

Support Provided by NIAID

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org

800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org